ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1957

Adalimumab-Associated Pauci-Immune Glomerulonephritis: Coincidence or Causation Effect?

Session Information

Category: Trainee Case Report

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Patel, Nirav N., Johnston Memorial Hospital, Abingdon, Virginia, United States
  • Spangler, Emma, Johnston Memorial Hospital, Abingdon, Virginia, United States
  • Annamaraju, Pavan, Johnston Memorial Hospital, Abingdon, Virginia, United States
Introduction

Adalimumab is a TNF-blocker used in the treatment of hidradenitis suppurutiva (HS). Infections, lupus-like syndrome, and lymphoma are known safety concerns with TNF-blockers. We report a rare case of adalimumab associated pauci-immune crescentric GN (PICGN) in a patient with HS.

Case Description

A 19-yr-old male with a history of HS on adalimumab for 6 months was seen on 4/1/20 with a fever of 103°F, cough & epistaxis for 2 weeks. CT sinuses showed polyps and sinusitis. He was treated with antibiotics for sinusitis. CT chest, nasal PCR for COVID-19, blood, and urine cultures were negative. By hospital day 8, he remained febrile and developed AKI [Creatinine (Cr)1.9 mg/dl; baseline of 0.8 mg/dl]. Physical exam showed chronic scarred skin lesions on the chest and axilla with no signs of infection or rash. Hematuria and microalbuminuria were noted. Ultrasound showed renomegaly. Inflammatory markers were high (CRP 254 mg/L, Ferritin 1059 ng/mL). PR3-ANCA antibody was positive 530 IU/mL. A renal biopsy confirmed PICGN (Fig 1). Bone marrow biopsy showed no evidence of hemophagocytosis. The patient was treated with pulse doses of steroids and rituximab and plasma exchange (peak cr 6.4 mg/dl). On a 3-week follow up creatinine improved to 1.8 mg/dl suggesting a favorable outcome. The patient never required dialysis.

Discussion

AKI, microscopic hematuria, and proteinuria can be seen in a febrile illness. However, epistaxis and renomegaly prompted us to check for ANCA serology. To our knowledge, this is the first case of adalimumab associated PICGN in a patient with HS. Interestingly, our patient is much younger compared to previously reported cases (mean 51.4 years). It is possible that adalimumab may be unrelated to the vasculitis; however, due to a strong temporal association, it was felt to be the culprit agent. Nephrologists must be aware of the renal side effects of this class of drugs.

Fig 1.Necrotizing Crescent